Indatuximab ravtansine

Ravtansine_ADCs.svg

Indatuximab ravtansine is an antibody-drug conjugate (ADC) designed for the treatment of various types of cancer. It is composed of a monoclonal antibody linked to a cytotoxic agent, specifically ravtansine, which is a derivative of the potent microtubule-disrupting agent maytansine.

Mechanism of Action

Indatuximab ravtansine targets the CD138 antigen, which is commonly overexpressed on the surface of multiple myeloma cells and other hematologic malignancies. Upon binding to CD138, the ADC is internalized by the cancer cell, where the cytotoxic agent ravtansine is released. Ravtansine then binds to tubulin, disrupting the microtubule network, which is essential for cell division, ultimately leading to cell death.

Clinical Development

Indatuximab ravtansine has been evaluated in several clinical trials for its efficacy and safety in treating multiple myeloma and other cancers. Early-phase trials have shown promising results, with significant anti-tumor activity and manageable side effects.

Side Effects

Common side effects of indatuximab ravtansine include fatigue, nausea, peripheral neuropathy, and thrombocytopenia. These side effects are generally consistent with those observed with other antibody-drug conjugates.

Current Status

As of the latest updates, indatuximab ravtansine is still under investigation in clinical trials. It has not yet received approval from major regulatory agencies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

See Also

• Antibody-drug conjugate
• Multiple myeloma
• CD138
• Maytansine